TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31091608

Group type: EXPERIMENTAL
Intervention: Two-dose Hepatitis B vaccine (HepB) administered on a 0-6 month schedule
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Three-dose Hepatitis B vaccine (HepB) administered on a 0-1-6 month schedule
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Challenge dose of Hepatitis B vaccine (HepB)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Participants with anti-HBs titer <4, 4-6, and 7-9 mIU/ml at follow-up
Number of subjects: 629
Study: 28577674

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) for STEMI
Number of subjects: 2679

Group type: COMPARATOR
Intervention: Control groups (no specific intervention mentioned)
Number of subjects: 2679
Study: 25460337

Group type: EXPERIMENTAL
Intervention: Keys to Healthy Family Child Care Homes intervention
Number of subjects: 1500000
Study: 23065023

Group type: EXPERIMENTAL
Intervention: Active compound (200 μg selenium, 30 mg zinc, 2 mg vitamin A, 180 mg vitamin C, 30 mg vitamin E)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Active compound
Number of subjects: 411
Study: 21684109

Group type: EXPERIMENTAL
Intervention: Femtosecond laser keratome
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mechanical keratome
Number of subjects: 51
Study: 18723240

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening annually for 4 years
Number of subjects: 3206

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 3206
Study: 16456417

Group type: EXPERIMENTAL
Intervention: Pureed beef
Number of subjects: 88

Group type: COMPARATOR
Intervention: Iron-fortified infant cereal
Number of subjects: 88
Study: 15360790

Group type: EXPERIMENTAL
Intervention: Alerted clinicians (received the alert)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Control clinicians (did not receive the alert)
Number of subjects: 1076
Study: 11265827

Group type: EXPERIMENTAL
Intervention: Safer Choices program
Number of subjects: 20
Study: 9408114

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) maintenance treatment (0.4 g/kg weekly)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5
Study: 8496997

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (target, < 24 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Late enteral feeding (target, 72 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 52

Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 52
Study: 2894489

Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: prenalterol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: phentolamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: angiotensin II
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: frusemide
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31019117

Group type: EXPERIMENTAL
Intervention: Anterior subcutaneous transposition of the ulnar nerve
Number of subjects: 55

Group type: COMPARATOR
Intervention: Simple decompression of the ulnar nerve
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (comparison)
Number of subjects: 55
Study: 27769562

Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Number of subjects: 1620

Group type: COMPARATOR
Intervention: 14-day triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily)
Number of subjects: 1620
Study: 24626605

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (20 sessions, 5 times per week for 4 weeks at 32-33 °C)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Home-based exercise (demonstrated by a physiotherapist and followed by an exercise manual)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 69
Study: 24139140

Group type: EXPERIMENTAL
Intervention: Complex implementation strategy (guideline facilitator visits, stratification tools, quality reports)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Simple implementation strategy
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Complex implementation strategy
Number of subjects: 2700
Study: 20942614

Group type: EXPERIMENTAL
Intervention: Two tablets of ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: One tablet of ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 19032172

Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 6.66 mg morphine equivalents, twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 13.3 mg morphine equivalents, twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 20 mg morphine equivalents, twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) (all doses)
Number of subjects: 45
Study: 16364595

Group type: EXPERIMENTAL
Intervention: Octyl-2-cyanoacrylate (Dermabond)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 45
Study: 11062193

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg perorally once daily for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg bid for 10 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both telithromycin and clarithromycin
Number of subjects: 20
Study: 9516902

Group type: EXPERIMENTAL
Intervention: BAYx 1005
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8436153

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg and Captopril 25 mg (combined treatment)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3717319

Group type: EXPERIMENTAL
Intervention: Contralateral therapy to the normal extremity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 20
Study: 31364169

Group type: EXPERIMENTAL
Intervention: CCBT+MCBT (child-focused CBT with CBT for maternal anxiety disorder)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CCBT+MCI (child-focused CBT with intervention targeting mother-child interaction)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CCBT+Con (child-focused CBT with nonspecific control interventions)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CCBT+MCI
Number of subjects: 211
Study: 30591062

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 16
Study: 27558577

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU/month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU/month
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU/month (after adjustment)
Number of subjects: 90
Study: 24772594

Group type: EXPERIMENTAL
Intervention: G-suit
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no G-suit)
Number of subjects: 10
Study: 23321187

Group type: EXPERIMENTAL
Intervention: Pelvic floor biofeedback training
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1 mg tolterodine, orally, twice daily
Number of subjects: 45
Study: 20860068

Group type: EXPERIMENTAL
Intervention: Venlafaxine (50-75 mg/day depending on weight)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 38
Study: 18546233

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 15957511

Group type: EXPERIMENTAL
Intervention: Pulsed magnetic field therapy (PMFT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 25
Study: 12500022

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily) in type IIa dyslipidemia
Number of subjects: 265

Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily) in type IIa dyslipidemia
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily) in type IIb dyslipidemia
Number of subjects: 265

Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily) in type IIb dyslipidemia
Number of subjects: 265
Study: 10231206

Group type: EXPERIMENTAL
Intervention: Oral metronidazole (OM) 500 mg for adults, 7‐10 mg/kg for children, administered 2‐3 hours before operation and continued postoperatively every 8 hours for three doses if mild to severely inflamed; for complicated appendicitis, the same dose for 3 to 6 days depending on pus presence.
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Ceftizoxime administered 2 to 3 hours before operation and postoperatively every 6 hours for three doses if mild to severely inflamed; complicated cases received penicillin, chloramphenicol, and gentamicin for 3 to 6 days depending on pus presence.
Number of subjects: 1083
Study: 8744845

Group type: EXPERIMENTAL
Intervention: Fixed combination of carteolol 2% and pilocarpine 2% (CBS 341 A) eye-drops
Number of subjects: 28

Group type: COMPARATOR
Intervention: Carteolol 2% alone
Number of subjects: 28
Study: 1986887

Group type: EXPERIMENTAL
Intervention: High-flow resistance breathing circuit
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Threshold-resistor breathing circuit
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (other breathing circuits)
Number of subjects: 12
Study: 6849168

Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (A-CA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 44
Study: 31865938

Group type: EXPERIMENTAL
Intervention: FPG ≥4.5 mmol/L
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: FPG ≥5.1 mmol/L
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Presence of one or more risk factors
Number of subjects: 589

Group type: COMPARATOR
Intervention: Risk factor-based selective screening
Number of subjects: 589
Study: 29899982

Group type: EXPERIMENTAL
Intervention: Text messaging survey
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1014
Study: 25304282

Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis (MRA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Glaucoma probability score (GPS)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Discriminant functions
Number of subjects: 230
Study: 24372613

Group type: EXPERIMENTAL
Intervention: 200 mg of l-theanine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg of l-theanine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 600 mg of l-theanine
Number of subjects: 14
Study: 22158729

Group type: EXPERIMENTAL
Intervention: Low protein diet (0.5 g protein · kg BW(‐1) · d(‐1))
Number of subjects: 37

Group type: COMPARATOR
Intervention: High protein diet (2.0 g protein · kg BW(‐1) · d(‐1))
Number of subjects: 37
Study: 20518951

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (GS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 18339272

Group type: EXPERIMENTAL
Intervention: Oral metoprolol treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Oral rehydration salt treatment
Number of subjects: 103
Study: 16355944

Group type: EXPERIMENTAL
Intervention: ketamine, 0.5 mg/kg
Number of subjects: 59

Group type: COMPARATOR
Intervention: saline, 2 mL
Number of subjects: 59

Group type: COMPARATOR
Intervention: ketamine, 1.2 mg/kg
Number of subjects: 59
Study: 12617466

Group type: EXPERIMENTAL
Intervention: Rapeseed oil-based diet rich in mono- and polyunsaturated FA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control diet rich in saturated FA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FA 18:0 and 20:3
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FA 20:5 and 22:6
Number of subjects: 75
Study: 9706940

Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream (EMLA)
Number of subjects: 538
Study: 7876652

Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 2 months (Group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 6 months (Group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 2213800

Group type: EXPERIMENTAL
Intervention: Dimethicone/antacid (Asilone Gel)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Alginate/antacid (Gaviscon liquid)
Number of subjects: 53
Study: 468672

Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 30137529

Group type: EXPERIMENTAL
Intervention: TXT (one session of telephone counseling plus 2 weeks of text messaging; N = 44)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard Care control group (N = 22)
Number of subjects: 66
Study: 28803333

Group type: EXPERIMENTAL
Intervention: 3.75 mg TLV
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 7.5 mg TLV
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 15 mg TLV
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy adults (control)
Number of subjects: 43
Study: 26248955

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks in genotype 1a patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 24 weeks in genotype 1b patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
Number of subjects: 104
Study: 24917527

Group type: EXPERIMENTAL
Intervention: Psychological intervention and oral health education before and after treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Regular doctor's advice after treatment (Control)
Number of subjects: 84
Study: 21178180

Group type: EXPERIMENTAL
Intervention: Crystalline l-Thr added to basal diet (60% of NRC recommendation in Exp. 1 and 20-60% in Exp. 2)
Number of subjects: 14
Study: 19414053

Group type: EXPERIMENTAL
Intervention: Low dose alcohol (0.2 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose alcohol (0.4 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task performance
Number of subjects: 0
Study: 17589826

Group type: EXPERIMENTAL
Intervention: Standard single bundle ACL reconstruction with lateral extraarticular reconstruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double bundle ACL reconstruction
Number of subjects: 20
Study: 16336114

Group type: EXPERIMENTAL
Intervention: Intervention group (family physical activity and parent education about diet and activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study: 12151972

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2 intravenously on days 1-5) followed by interferon-α-2a (2 × 106 U/m2 subcutaneously on days 22-26)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fludarabine and interferon-α-2a regimen
Number of subjects: 21
Study: 9840032

Group type: EXPERIMENTAL
Intervention: 2D MR DSA
Number of subjects: 22

Group type: COMPARATOR
Intervention: X-ray Angiography (XRA)
Number of subjects: 22
Study: 7988196

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.20 ppm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Filtered Purified Air (FPA) exposure
Number of subjects: 10
Study: 2726771

Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 10 mg single infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 40 mg single infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 10 mg three infusions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal antibody (mAb) 40 mg three infusions
Number of subjects: 10
Study: 29512827

Group type: EXPERIMENTAL
Intervention: 170 mug LPP administered subcutaneously over 3 weeks
Number of subjects: 554
Study: 25826476

Group type: EXPERIMENTAL
Intervention: Life story book
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rummage box
Number of subjects: 5

Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 5
Study: 25424512

Group type: EXPERIMENTAL
Intervention: Exercise + Diet Quality + Weight Maintenance Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise + Diet Quality + Weight Loss Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise Only (Control) Intervention
Number of subjects: 0
Study: 24359543

Group type: EXPERIMENTAL
Intervention: Complex intervention for GPs including interactive workshops, audit and feedback reports, automated electronic prompts, and a recommendation for delayed antimicrobial treatment.
Number of subjects: 2038

Group type: EXPERIMENTAL
Intervention: Multimedia applications and information leaflets for patients.
Number of subjects: 2038
Study: 20945468

Group type: EXPERIMENTAL
Intervention: Glucommander
Number of subjects: 153
Study: 18387160

Group type: EXPERIMENTAL
Intervention: Sevelamer (3.0 g/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Colestimide (3.0 g/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sevelamer with CaCO3 (3.0 g/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Colestimide with CaCO3 (3.0 g/day)
Number of subjects: 62
Study: 16343856

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin XR 1000 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg
Number of subjects: 12
Study: 14677216

Group type: EXPERIMENTAL
Intervention: Right hemiparesis patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Left hemiparesis patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Functional ability assessment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Stance unsteadiness and asymmetry
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (15 age-matched individuals)
Number of subjects: 104
Study: 11273797

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 9391723

Group type: EXPERIMENTAL
Intervention: Continuous infusion of heparin based on initial patient-specific dose per unit weight and adjustments during CPB based on reference heparin concentration.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monitoring group using bolus administration of heparin calculated by the Hepcon instrument during CPB.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received similar doses of heparin and protamine, and had similar transfusion requirements.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monitoring group prior to CPB.
Number of subjects: 40
Study: 7933485

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal buprenorphine (0.05 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal buprenorphine (0.075 mg)
Number of subjects: 0
Study: 3328281

Group type: EXPERIMENTAL
Intervention: Sucralfate 1.0g qid for 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sucralfate treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: ASA treatment
Number of subjects: 24
Study: 30698458

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray prior to SC heparin injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Water spray (placebo) prior to SC heparin injection
Number of subjects: 64
Study: 29600809

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) at 24 Gy to the 50% isodose targeting mesial structures
Number of subjects: 58

Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both SRS and ATL
Number of subjects: 58
Study: 28611897

Group type: EXPERIMENTAL
Intervention: Evidence-based coaching intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual post-ED care
Number of subjects: 69
Study: 25856270

Group type: EXPERIMENTAL
Intervention: POPET-AR group (mobile phone application for AR patients)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: POPET-Asthma group (mobile phone application for asthma patients)
Number of subjects: 327
Study: 22718278

Group type: EXPERIMENTAL
Intervention: G135E mutation in HOXB13
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (1,536 subjects)
Number of subjects: 96